Oct 13, 2021
|
Ardelyx Provides Corporate Update Following Type A Meeting with FDA
|
Sep 3, 2021
|
Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial
|
Aug 13, 2021
|
Ardelyx Reports Second Quarter 2021 Financial Results
|
Jul 29, 2021
|
Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
|
Jul 19, 2021
|
Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
|
Jun 7, 2021
|
Ardelyx Announces Presentations at ERA-EDTA Virtual Congress 2021
|
May 25, 2021
|
Ardelyx to Present at the Jefferies 2021 Virtual Healthcare Conference
|
May 6, 2021
|
Ardelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights
|
Apr 29, 2021
|
Ardelyx Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
|
Apr 16, 2021
|
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|